Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)’s share price traded up 2.8% on Thursday . The stock traded as high as $5.29 and last traded at $5.20, with a volume of 1,118,501 shares changing hands. The stock had previously closed at $5.06.

Several equities research analysts recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Progenics Pharmaceuticals in a research note on Monday, March 14th. Brean Capital reaffirmed a “buy” rating on shares of Progenics Pharmaceuticals in a research note on Wednesday, June 15th. Jefferies Group reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Progenics Pharmaceuticals in a research note on Wednesday, April 6th. BTIG Research lowered their price objective on shares of Progenics Pharmaceuticals from $12.00 to $9.00 and set a “buy” rating for the company in a research note on Tuesday, March 15th. Finally, Zacks Investment Research raised shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $10.35.

The company’s 50-day moving average is $4.74 and its 200-day moving average is $4.74. The stock’s market capitalization is $382.60 million.

Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.05. During the same period in the previous year, the company posted ($0.15) earnings per share. The firm earned $2.50 million during the quarter, compared to analyst estimates of $3.27 million. The firm’s quarterly revenue was up 908.1% on a year-over-year basis. On average, analysts predict that Progenics Pharmaceuticals Inc. will post $0.12 earnings per share for the current year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.